Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Bladder: enfortumab vedotin + pembrolizumab & VESPER trial

Yohann Loriot, MD, PhD, Gustave Roussy Institute & University of Paris-Saclay, Paris, France, outlines the key bladder cancer data to takeaway from the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA. Dr Loriot goes into depth on the use of a enfortumab vedotin and pembrolizumab combination and the VESPER trial (NCT01812369) investigating perioperative chemotherapy for patients with locally advanced bladder cancer.